Cooley Advises Clinical Data in $1.2 Billion Sale to Forest Labs
Palo Alto, Calif. – March 2, 2011 – Cooley LLP announced it advised Clinical Data, Inc. (NASDAQ: CLDA), in its $1.2 billion sale to Forest Laboratories, Inc. (NYSE: FRX) announced last week. Forest will finance the transaction with existing cash. The transaction was approved by the boards of both companies and is expected to be completed in the second quarter of 2011, subject to customary closing conditions.
The Cooley team advising Clinical Data included partners Barbara Borden (M&A practice group head), Marc Recht, Robert Jones and Miguel Vega, special counsel Rama Padmanabhan and associates Rob Hadfield, Mike Chapin and Erin Walczewski. Antitrust partner Francis Fryscak, Compensation & Benefits partner Thomas Welk and Tax partner Dan Meehan also assisted in the transaction.
About Cooley LLP
Cooley's 650 attorneys have an entrepreneurial spirit and deep, substantive experience, and are committed to solving clients' most challenging legal matters. From small companies with big ideas to international enterprises with diverse legal needs, Cooley has the breadth of legal resources to enable companies of all sizes to seize opportunities in today's global marketplace. The Firm represents clients across a broad array of dynamic industry sectors, including technology, life sciences, venture capital, clean energy, real estate and retail.
The Firm has full-service offices in major business and technology centers nationwide: Palo Alto, CA, New York, NY, San Diego, CA, San Francisco, CA, Reston, VA, Broomfield, CO, Washington, DC, Boston, MA and Seattle, WA.